Drug Discovery Services Market to Reach US$67.3 Billion by 2035: Why This Is a Defining Decade for Pharma Innovation

Every breakthrough medicine begins long before clinical trials, regulatory approvals, or pharmacy shelves.

It starts with discovery.

Scientists spend years identifying disease targets, designing molecules, testing compounds, and validating potential therapies before a single drug candidate reaches patients. This early phase of pharmaceutical research has always been one of the most expensive and scientifically demanding parts of drug development.

Today, that landscape is changing rapidly.

According to Global Market Insights, the global drug discovery services market is projected to grow from US$21.5 billion in 2026 to an impressive US$67.3 billion by 2035, expanding at a strong 13.5% CAGR. This remarkable growth reflects more than just increasing investment—it signals a fundamental transformation in how the pharmaceutical industry discovers new medicines.

Artificial intelligence, contract research organizations (CROs), biologics, precision medicine, and biotech innovation are reshaping drug discovery faster than ever before.

For pharmaceutical professionals, researchers, biotech startups, and job seekers, this isn't just another market forecast. It represents one of the biggest career opportunities the industry has seen in decades.

Drug Discovery Services Market at a Glance

Why Is the Drug Discovery Services Market Growing So Fast?

The pharmaceutical industry has entered an era where speed, innovation, and efficiency are becoming just as important as scientific excellence.

Developing a new medicine traditionally requires more than a decade of research and billions of dollars in investment. Every failed experiment, delayed study, or unsuccessful clinical candidate increases development costs.

To overcome these challenges, pharmaceutical companies are transforming the way they conduct research.

Instead of building every capability internally, companies are increasingly collaborating with specialized drug discovery service providers and CROs that possess advanced scientific expertise, cutting-edge technologies, and scalable research infrastructure.

This shift is accelerating innovation while reducing costs and development timelines.

The Rise of CROs: Why Big Pharma Is Outsourcing Discovery

One of the strongest forces behind market growth is the increasing reliance on Contract Research Organizations (CROs).

Years ago, pharmaceutical companies performed nearly every stage of discovery in-house.

Today, that model has evolved.

Large pharmaceutical companies now outsource significant portions of early-stage drug discovery to specialized partners that offer expertise in medicinal chemistry, computational biology, screening technologies, and molecular biology.

This allows pharmaceutical companies to:

• Reduce research costs

• Access specialized scientific expertise

• Accelerate drug discovery timelines

• Increase flexibility

• Focus internal teams on strategic innovation

• Expand therapeutic research without major infrastructure investments

For CROs, this represents a massive business opportunity.

For scientists, it means thousands of new jobs across discovery research, biology, chemistry, computational science, and regulatory functions.

Artificial Intelligence Is Revolutionizing Drug Discovery

Perhaps the most transformative driver behind this market expansion is Artificial Intelligence (AI).

Drug discovery has traditionally relied on years of laboratory experimentation and trial-and-error approaches.

AI is changing that.

Modern AI platforms can analyze billions of biological data points in a fraction of the time required by traditional research methods.

Today, AI assists scientists by:

• Identifying novel disease targets

• Predicting protein structures

• Designing new molecules

• Optimizing lead compounds

• Reducing experimental failures

• Prioritizing drug candidates

• Accelerating biomarker discovery

Instead of replacing scientists, AI is becoming an intelligent research partner that enables teams to make faster and better-informed decisions.

This combination of computational intelligence and laboratory science is dramatically improving research productivity.

Target Identification Has Become Smarter Than Ever

Every successful medicine begins with identifying the right biological target.

A target may be:

• Protein

• Enzyme

• Receptor

• Gene

• RNA molecule

• Cellular pathway

Choosing the wrong target can lead to years of unsuccessful research.

According to the report, target selection accounts for approximately 10.3% of the global drug discovery services market, highlighting its importance within the discovery workflow.

Historically, researchers relied on:

• Scientific literature

• Animal models

• Laboratory experiments

• Genetic studies

Today, AI-powered bioinformatics platforms analyze massive genomic, proteomic, and clinical datasets to uncover previously unknown therapeutic targets.

This dramatically increases the probability of discovering innovative medicines.

Chemistry Services Continue to Dominate

While AI receives much of the attention, chemistry remains the backbone of pharmaceutical discovery.

The report indicates that chemistry services account for 54.6% of the global drug discovery services market, making it the largest service segment.

These services include:

Medicinal Chemistry

Scientists modify molecular structures to improve drug effectiveness and reduce side effects.

Structure-Based Drug Design

Advanced computer modeling helps researchers design molecules that precisely interact with disease targets.

Parallel Synthesis

Researchers generate multiple chemical variants simultaneously to identify the most promising candidates.

Process Chemistry

Scientists optimize manufacturing methods that will later support commercial production.

Cheminformatics

Computational chemistry tools analyze chemical databases and predict molecular behavior before laboratory testing begins.

Without these specialized chemistry capabilities, modern pharmaceutical pipelines simply cannot function efficiently.

Small Molecules Still Lead the Market

Despite the rapid growth of biologics, gene therapy, and cell therapy, small-molecule drugs continue to dominate global drug discovery services.

According to the report:

Small molecules represent 58.6% of global drug discovery services revenue in 2025.

Why?

Because they offer several advantages:

• Lower manufacturing costs

• Easier oral administration

• Well-established regulatory pathways

• Proven clinical development processes

• Broad therapeutic applications

• Greater global accessibility

Many of today's most successful medicines remain small molecules, particularly across cardiovascular disease, oncology, diabetes, infectious diseases, and central nervous system disorders.

Biologics Are Creating a New Wave of Discovery

Although small molecules remain dominant, biologics are becoming one of the fastest-growing areas in pharmaceutical R&D.

Biologics include:

• Monoclonal antibodies

• Recombinant proteins

• Cell therapies

• Gene therapies

• RNA therapeutics

• Advanced biologic medicines

These therapies require highly specialized discovery expertise.

Unlike traditional chemistry-based research, biologic discovery involves:

• Protein engineering

• Cell-line development

• Immunology

• Molecular biology

• Bioanalytics

• Biomarker discovery

As biologics continue expanding across oncology, autoimmune diseases, and rare disorders, demand for specialized drug discovery services is expected to rise significantly.

Why Biotech Companies Are Fueling Market Growth

The pharmaceutical landscape is no longer dominated solely by multinational companies.

Thousands of biotechnology startups are driving innovation worldwide.

However, most emerging biotech companies lack the infrastructure required to conduct complete discovery programs independently.

Instead, they partner with integrated CROs that provide end-to-end services.

These partnerships include:

• Target validation

• Assay development

• Hit identification

• Lead optimization

• DMPK studies

• Toxicology support

• IND-enabling research

This collaborative model allows biotech innovators to focus on science while leveraging external expertise to accelerate development.

Career Opportunities Created by This Market Boom

Rapid growth in drug discovery services means increased demand for highly skilled professionals across pharmaceutical research.

Some of the fastest-growing career opportunities include:

Drug Discovery Scientist

Researchers responsible for identifying and validating new therapeutic candidates.

Medicinal Chemist

Designs and synthesizes molecules with improved therapeutic properties.

Computational Biologist

Uses AI and bioinformatics to identify drug targets and predict biological outcomes.

Bioinformatics Scientist

Analyzes genomic and molecular datasets to guide discovery research.

Pharmacologist

Evaluates drug activity, efficacy, and safety.

Molecular Biologist

Investigates disease mechanisms and therapeutic pathways.

AI Drug Discovery Specialist

Develops machine learning models for pharmaceutical research.

Clinical Translation Scientist

Bridges laboratory discoveries with clinical development.

Project Manager – Drug Discovery

Coordinates multidisciplinary discovery programs.

CRO Research Scientist

Works with pharmaceutical sponsors across multiple therapeutic areas.

Skills That Will Be Most Valuable by 2035

As discovery becomes increasingly technology-driven, employers will seek professionals with interdisciplinary expertise.

Future-ready skills include:

• Artificial Intelligence

• Machine Learning

• Bioinformatics

• Computational Chemistry

• Medicinal Chemistry

• Molecular Biology

• Protein Engineering

• Pharmacology

• Systems Biology

• Multi-omics Data Analysis

• Drug Design Software

• Laboratory Automation

• Regulatory Science

• Scientific Writing

• Cross-functional Collaboration

Professionals who combine biological knowledge with computational skills are expected to be among the most sought-after talent in the coming decade.

What This Means for India's Pharmaceutical Industry

India already plays a globally significant role in pharmaceutical manufacturing.

Now, the country is steadily strengthening its position in drug discovery and research services.

Indian CROs, biotech startups, Global Capability Centers (GCCs), and pharmaceutical R&D hubs are attracting increasing investments from international companies seeking high-quality scientific capabilities.

Cities such as:

• Hyderabad

• Bengaluru

• Ahmedabad

• Pune

• Mumbai

• Chennai

continue to expand their presence in pharmaceutical innovation.

As global outsourcing grows, India is well positioned to become one of the world's leading drug discovery destinations.

Challenges That Still Need to Be Solved

Despite impressive growth, several challenges remain.

The industry must continue addressing:

• High discovery failure rates

• Rising R&D costs

• Increasing regulatory expectations

• Data integration challenges

• Talent shortages

• Intellectual property management

• Ethical AI implementation

• Complex biologics manufacturing

Organizations that successfully combine scientific excellence with digital innovation will be best positioned for long-term success.

The Future of Drug Discovery

Drug discovery is no longer driven by laboratory science alone.

It is becoming an integrated ecosystem where:

• AI accelerates research.

• Biologists uncover disease mechanisms.

• Chemists design better molecules.

• Data scientists analyze complex biological systems.

• CROs provide specialized capabilities.

• Biotech startups drive innovation.

• Pharmaceutical companies coordinate global development.

Together, these advances are creating a faster, smarter, and more collaborative model of medicine discovery.

The projected growth to US$67.3 billion by 2035 reflects the industry's confidence that this transformation is only beginning.

Key Takeaways

• The global drug discovery services market is expected to reach US$67.3 billion by 2035.

• The market is projected to grow at a 13.5% CAGR.

• AI is transforming target identification, lead optimization, and candidate selection.

• CRO outsourcing continues to accelerate pharmaceutical innovation.

• Chemistry services remain the largest market segment.

• Small molecules still dominate global drug pipelines.

• Biologics are driving new research investments.

• India is emerging as a leading global drug discovery hub.

• The market expansion will create significant career opportunities across pharmaceutical R&D, computational biology, AI, chemistry, and biotechnology.

Why This Matters for Pharma Professionals

At BIG PHARMA JOBS, we closely track global pharmaceutical innovation because every scientific breakthrough creates new career opportunities.

As pharmaceutical companies invest more heavily in drug discovery, demand for skilled professionals in research, AI, medicinal chemistry, bioinformatics, regulatory affairs, and clinical development will continue to rise.

Whether you're a fresher entering pharmaceutical research or an experienced scientist looking for your next opportunity, understanding where the industry is heading can help you build a future-ready career in one of the fastest-growing sectors of global healthcare.